People · Operator
Named in public records as an officer, director or promoter · active 2015–2019 · Pharma, Biotechnology, Other Technology
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Alessa Therapeutics, Inc. | — | Pharma | Series B | $31.6M | $129.6M | 2019 |
| Mitokinin, Inc. | — | Biotechnology | Series A | $9.5M | $180.8M | 2017 |
| Invenio Imaging, Inc. | — | Other Technology | Seed | $7.5M | $78.9M | 2015 |
Doug Crawford at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Doug Crawford on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Douglas Crawford | 3 | 8 |
| Peter Parker | 2 | 6 |
| Richard Lim | 1 | 14 |
| Cam Gallagher | 1 | 7 |
| John Maroney | 1 | 3 |
| Zachary Collins | 1 | 3 |
| Annie Mitsak | 1 | 2 |
| Nicholas Hertz | 1 | 2 |
| Steve Tregay | 1 | 2 |
| Johannes Fruehauf | 1 | 2 |
| Jay Trautman | 1 | 2 |
| DANIEL ORRINGER | 1 | 1 |
| Xiaoliang Xie | 1 | 1 |
| Christian Freudiger | 1 | 1 |
| Daniel De Roulet, Jr. | 1 | 1 |
| Pamela Munster | 1 | 1 |
| Michael Ming-Yih Wu | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.